Beye Aida, Pindur Gerhard
Centre Hospitalier Nord Deux-Sèvres, Bressuire, France.
Saarland University Hospital, Homburg, Germany.
Clin Hemorheol Microcirc. 2017;67(3-4):261-266. doi: 10.3233/CH-179207.
Cerebrovascular diseases are considered in a different way concerning their etiology with regard to arterial and venous occlusion. The role of thrombophilia in this context remains undetermined. For this reason, a case-control study was conducted including a total of 202 patients (154 females, 48 males) aged from 18 to 76 years (mean: 39.8 years) suffering either from cerebral sinus venous thrombosis (n = 101) or from arterial ischemic stroke (n = 101). Study groups were evaluated on the basis of age- and gender-matched pairs. Gene mutations of factor V-1691 (factor V Leiden) and prothrombin-20210 being considered as the most common thrombophilia markers were analyzed in this study. Factor V Leiden-mutations were found in 16.8% of patients with cerebral sinus venous thrombosis (CVT) and in 17.8% of patients with arterial ischemic stroke (AIS), which was significantly more frequent than in controls at a rate of 4.95% (ORs: 3.89 and 4.16). Prothrombin-mutations were significantly more frequent in CVT at a rate of 14.9% versus 2.97% in controls (OR: 5.70). This does not apply for AIS showing a rate of 4.95% prothrombin-mutations. Rates of factor V Leiden-mutations are not different in CVT compared with AIS. In contrast, however, prothrombin-mutations were significantly more frequent in CVT than in AIS with a rate of 14.9% versus 4.95% (OR 3.35). Furthermore, 3 cases with combined heterozygosity of factor V Leiden- and prothrombin-mutation have been identified in CVT, but not in AIS or controls. All of the above mentioned mutations were exclusively heterozygous. We conclude from these data that thrombophilia in terms of factor V Leiden genotype is a risk factor for both CVT and AIS in equal measure. In contrast, prothrombin-20210-mutations were different playing a significant role in the pathogenesis of cerebral sinus vein thrombosis, but not in arterial ischemic stroke. Also, the combined occurrence of heterozygous prothrombin- and factor V Leiden-mutation clearly favors the emergence of cerebral sinus venous thrombosis. Therefore, in terms of thrombophilia such as investigated in this study, pathogenesis of arterial and venous occlusions in cerebrovascular disease has to be regarded as different.
脑血管疾病在病因方面,根据动脉和静脉闭塞情况有着不同的考量方式。在这种情况下,血栓形成倾向的作用仍未明确。因此,开展了一项病例对照研究,共纳入202例患者(154例女性,48例男性),年龄在18至76岁之间(平均:39.8岁),这些患者患有脑静脉窦血栓形成(n = 101)或动脉缺血性卒中(n = 101)。研究组基于年龄和性别匹配的配对进行评估。本研究分析了被视为最常见血栓形成倾向标志物的因子V - 1691(因子V莱顿)和凝血酶原 - 20210的基因突变。在脑静脉窦血栓形成(CVT)患者中,16.8%发现有因子V莱顿突变,在动脉缺血性卒中(AIS)患者中,17.8%发现有该突变,这一比例显著高于对照组的4.95%(比值比:3.89和4.16)。凝血酶原突变在CVT患者中的发生率显著更高,为14.9%,而对照组为2.97%(比值比:5.70)。这在AIS患者中并不适用,其凝血酶原突变率为4.95%。因子V莱顿突变在CVT患者中的发生率与AIS患者相比无差异。然而,相比之下,凝血酶原突变在CVT患者中的发生率显著高于AIS患者,分别为14.9%和4.95%(比值比3.35)。此外,在CVT患者中鉴定出3例因子V莱顿和凝血酶原突变的复合杂合子病例,但在AIS患者或对照组中未发现。上述所有突变均为纯合子。从这些数据我们得出结论,就因子V莱顿基因型而言,血栓形成倾向在同等程度上是CVT和AIS的危险因素。相比之下,凝血酶原 - 20210突变则不同,它在脑静脉窦血栓形成的发病机制中起重要作用,但在动脉缺血性卒中中并非如此。而且,凝血酶原和因子V莱顿突变的复合杂合子的出现显然更易引发脑静脉窦血栓形成。因此,就本研究中所调查的血栓形成倾向而言,脑血管疾病中动脉和静脉闭塞的发病机制必须被视为不同。